Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ADAG with free AI briefings, catalyst countdowns, and dilution alerts.

ADAG · Adagene Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$127.9M Cash on Hand
79.7mo Cash Runway
Follow ADAG by email Get an email when ADAG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADAG, unsubscribe in one click. Privacy

📣 What ADAG Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Amezalpat (TPST-1120) Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Tobemstomig Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Tiragolumab Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Pembrolizumab & ADG106 (Phase Ib) Advanced Solid Tumor Phase 1/2 · NCT05491083 Recruiting
PD-1 antibody injection Solid Tumor Phase 1/2 · NCT04775680 Terminated
Imdatifan (NKT2152) Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Anti-CD137 Agonistic Monoclonal Antibody ADG106 HER2-negative Breast Cancer Phase 1/2 · NCT05275777 Active not recruiting
Anti-LILRB2 Monoclonal Antibody IO-108 Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Doxorubicin HER2-negative Breast Cancer Phase 1/2 · NCT05275777 Active not recruiting
Muzastotug (ADG126) Advanced/Metastatic Solid Tumors Phase 1/2 · NCT04645069 Completed
anti PD1 drug Advanced/Metastatic Solid Tumors Phase 1 · NCT04501276 Completed
Anti-CD137 Agonistic Monoclonal Antibody ADG206 Advanced/Metastatic Solid Tumors Phase 1 · NCT05614258 Active not recruiting
Firastotug (ADG116) Advanced/Metastatic Solid Tumors Phase 1 · NCT04501276 Completed

Also used in these trials (approved or third-party drugs, not ADAG's own candidates): Nivolumab, Tocilizumab, Pembrolizumab, Paclitaxel, Cyclophosphamide, Bevacizumab, Atezolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADAG holds $127.9M in cash and short-term investments and burns about $4.8M/quarter from operations, an estimated runway of 79.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADAG files for a raise →

👥 Who Owns ADAG

Insiders 1.2% Other 5%+ holders 28.5% Institutions (46 holders) 34.5% Public and other holders 35.8%
HolderTypeShares% of sharesAs of
HAN 2020 Irrevocable Trust 5%+ holder (13D) 9,390,439 15.85% 2026-06-05
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 6,666,666 11.26% 2026-04-30
Smith Vincent C 5%+ holder (13G) 5,095,351 8.60% 2025-12-31
Chernett Jorey 5%+ holder (13G) 2,389,060 4.03% 2026-03-16
Mickael Yannick Chane-Du
Chief Strategy Officer
Insider 467,525 0.79% 2026-03-18
Qinghai Zhao
Chief Manufacturing Officer
Insider 130,214 0.22% 2026-03-18
Peter Luo
Chief Executive Officer, Director
Insider 88,535 0.15% 2026-09-16
Ulf Grawunder
Director · +85,000 options
Insider 25,000 0.04% 2026-03-17
Man Kin Tam
Chief Financial Officer, Director
Insider 12,000 0.02% 2026-09-23
Chunfang Gu
Executive Director of Finance
Insider 5,775 0.01% 2026-09-30
Ling Zhou
ED of Human Resources
Insider 2,969 0.01% 2026-03-18
Cuong V Do
Director · +110,000 options
Insider 2,000 0.00% 2026-08-14

Share count 59,231,993 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADAG picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADAG and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.